Gemcitabine-Based Combination Chemotherapy Followed by Radiation With Capecitabine as Adjuvant Therapy for Resected Pancreas Cancer
Journal Article
·
· International Journal of Radiation Oncology, Biology and Physics
- Department of Internal Medicine, University of Michigan, Ann Arbor, MI (United States)
- Department of Radiation Oncology, University of Michigan, Ann Arbor, MI (United States)
- Biostatistics Core Facility, University of Michigan, Ann Arbor, MI (United States)
- Department of Surgery, University of Michigan, Ann Arbor, MI (United States)
- Department of Pathology, University of Michigan, Ann Arbor, MI (United States)
- Department of Radiology, University of Michigan, Ann Arbor, MI (United States)
- Department of Nursing, University of Michigan, Ann Arbor, MI (United States)
Purpose: To report outcomes for patients with resected pancreas cancer treated with an adjuvant regimen consisting of gemcitabine-based combination chemotherapy followed by capecitabine and radiation. Patients and Methods: We performed a retrospective review of a series of patients treated at a single institution with a common postoperative adjuvant program. Between January 2002 and August 2006, 43 resected pancreas cancer patients were offered treatment consisting of 4, 21-day cycles of gemcitabine 1 g/m{sup 2} intravenously over 30 min on Days 1 and 8, with either cisplatin 35 mg/m{sup 2} intravenously on Days 1 and 8 or capecitabine 1500 mg/m{sup 2} orally in divided doses on Days 1-14. After completion of combination chemotherapy, patients received a course of radiotherapy (54 Gy) with concurrent capecitabine (1330 mg/m{sup 2} orally in divided doses) day 1 to treatment completion. Results: Forty-one patients were treated. Median progression-free survival for the entire group was 21.7 months (95% confidence interval 13.9-34.5 months), and median overall survival was 45.9 months. In multivariate analysis a postoperative CA 19-9 level of >=180 U/mL predicted relapse and death. Toxicity was mild, with only two hospitalizations during adjuvant therapy. Conclusions: A postoperative adjuvant program using combination chemotherapy with gemcitabine and either cisplatin or capecitabine followed by radiotherapy with capecitabine is tolerable and efficacious and should be considered for Phase III testing in this group of patients.
- OSTI ID:
- 21367555
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 5 Vol. 75; ISSN IOBPD3; ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
Similar Records
Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer
A Phase II Study of Fixed-Dose Rate Gemcitabine Plus Low-Dose Cisplatin Followed by Consolidative Chemoradiation for Locally Advanced Pancreatic Cancer
Phase 2 Trial of Induction Gemcitabine, Oxaliplatin, and Cetuximab Followed by Selective Capecitabine-Based Chemoradiation in Patients With Borderline Resectable or Unresectable Locally Advanced Pancreatic Cancer
Journal Article
·
Wed Nov 30 23:00:00 EST 2005
· International Journal of Radiation Oncology, Biology and Physics
·
OSTI ID:20788222
A Phase II Study of Fixed-Dose Rate Gemcitabine Plus Low-Dose Cisplatin Followed by Consolidative Chemoradiation for Locally Advanced Pancreatic Cancer
Journal Article
·
Sun Jul 01 00:00:00 EDT 2007
· International Journal of Radiation Oncology, Biology and Physics
·
OSTI ID:20951709
Phase 2 Trial of Induction Gemcitabine, Oxaliplatin, and Cetuximab Followed by Selective Capecitabine-Based Chemoradiation in Patients With Borderline Resectable or Unresectable Locally Advanced Pancreatic Cancer
Journal Article
·
Sat Mar 15 00:00:00 EDT 2014
· International Journal of Radiation Oncology, Biology and Physics
·
OSTI ID:22416492